Form 4: BioRestorative Therapies VP Francisco Silva Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Francisco Silva, VP of Research and Development at BioRestorative Therapies, reports a transaction involving common stock and stock options.
Summary
- On March 18, 2024, Francisco Silva, VP of Research and Development at BioRestorative Therapies, Inc., filed a Form 4.
- The filing reports the withholding of 17,193 common stock shares to cover withholding taxes at a price of $1.39.
- Following the transaction, Silva directly owns 147,451 shares of common stock and indirectly owns 12,136 shares through an IRA.
- The filing also details Silva's ownership of various stock options with different exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting changes in beneficial ownership, with neutral sentiment.
Industry Context
This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- Shareholders are informed about insider transactions, promoting transparency.
Key Dates
| Date | Description |
|---|---|
| 03/18/2024 | Date of transaction involving common stock. |
| 03/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.